A venture investment opportunity in a fast-growing clinical platform that addresses the main reasons for GLP-1 therapy failure — the lack of clinical support, insurance coverage, and long-term outcomes.
Regional focus of the project: United States (all 50 states).
Problem
Obesity is the most expensive systemic healthcare problem in the United States. This means:
- $480 billion in direct system costs annually
- 40% of adults suffer from obesity, and 75% already have comorbidities: diabetes, cardiovascular diseases, MASH, sleep apnea, depression — 14 of the 20 most expensive conditions
- 95% of Americans have insurance coverage for nutrition therapy, but fewer than 1% use it
- The GLP-1 market has exceeded $35 billion, yet 30% of patients discontinue treatment in the first month, and 54% stop before achieving clinical benefit
- Most regain weight within 18 months after discontinuing the medication
- The largest DTC platforms issue millions of prescriptions without doctor-patient interaction and without clinical support.
Solution and product
A single platform combining three components under one insurance-covered model:
- GLP-1 Prescribing: in-network across all 50 states, FDA-approved medications from Lilly and Novo Nordisk through the patient’s pharmacy, covered by insurance
- AI Dietitian “Ria”: available in 95 languages, integrated with medical records, labs, wearables, and CGM; patented AI nutrition tracker; over 100M AI messages exchanged and 1T+ patient records
- Dietitian Network: 2,000+ licensed RDs in all 50 states, 1-on-1 coaching at $0 cost to the patient, with a clinical AI copilot increasing the efficiency of every care hour
All three components form a single platform with unified insurance coverage. The clinical data moat deepens with every visit and cannot be replicated by competitors.
Brief market analysis
Metabolic health is one of the most structurally fast-growing segments in healthcare:
- $500B U.S. nutrition therapy market — largely untapped
- $35B+ GLP-1 drug market continues to grow
- 200M+ potential patients versus 110K active dietitians — a massive gap
- CMS ACCESS ($15B+ TAM) and GLP-1 Bridge ($20B+ TAM) open Medicare as a new channel
- Berry Street is the only platform that simultaneously has CMS approval, GLP-1 prescribing, AI Care, and insurance coverage.
Tangible and intangible assets
- The largest insurance network in the sector: ~135M commercially insured + ~60M publicly insured lives
- Cigna — national contract (March 2026, +19% rate increase); UnitedHealthcare and Aetna national participation; 30+ BCBS divisions; 120 group contracts
- The only RD network approved by CMS for outcomes-based Medicare (ACCESS program, ~36M lives)
- GLP-1 Bridge: the only consumer platform with a CMS prescriber network (~27M lives)
- Data moat: 1T+ patient records; Stanford clinical validation (the first peer-reviewed paper on AI health coaching); OpenAI Demo Day 2024 partner
- Partnerships: Novo Nordisk (LOI $2.6M, Phase 3 RFP finalist), Lilly (5K patient pilot), Amazon Health Benefits, Walmart Better Care, Mayo Clinic Diet, HelloFresh/Factor.
Current project status and achievements
The company demonstrates an exceptional growth trajectory: $70M+ ARR as of January 2026, 175K+ patients, and 1M+ visits since 2023.
- Revenue: $2M (FY23) → $17M (FY24) → $45M (FY25) → $80M+ (FY26E) — 26x growth in 3 years
- -5% weight loss in 60 days; +4.2% muscle mass in GLP-1 patients
- 9.1/10 provider satisfaction; 5.0★ Google Reviews (2.1K), 4.8★ App Store (2.6K)
- The acquisition of Healthify adds global AI scalability and industry-best clinical outcomes.
Team and personnel
The company was founded by entrepreneurs and executives with backgrounds in medicine, technology, and business. Key team members include: Noah Kotlove (CEO) — serial entrepreneur, 3 exits, scaled an app to 6M+ users, Wharton/Accenture; Anita Khosla (CPO) — ex-Amazon and Meta; Richard Fu (CCO) — ex-BlueCross BlueShield. The team includes 290+ employees from Meta, GoodRx, Zocdoc, Oscar, Grow Therapy, and Warby Parker. Investors include Khosla Ventures, Northzone, QuantumLight, FJ Labs, LeapFrog, and Village Global.
Key current and target project metrics
Current metrics: $70M+ ARR (January 2026), 175K+ patients across 50 states
- 26x growth over 3 years
- -5% weight in 60 days; +4.2% muscle mass (GLP-1)
- ~195M insured lives in network
- 100% renewal of key partners
Unit economics:
- GLP-1 Management: $110–130/patient/month, insurance-covered
- AI Care: $20–30/patient/month, insurance-covered
- Dietitian Care: ~$700 average revenue per patient, $0 out-of-pocket
Target metrics (FY26–FY29):
- $80M+ revenue by the end of FY26
- $160M+ (FY27) → $330M+ (FY28) → $500M+ (FY29)
- EBITDA break-even in FY27, 15%+ margin from FY28
- Medicaid launch in H2 2026; Medicare/Medicaid infrastructure.
Offer for the investor
A venture investment structure that предусматривает profit generation exclusively through growth in the company’s valuation and the subsequent sale of the ICLUB stake, with no dividend payouts.
- Minimum ticket: $10,000; venture model (returns through capitalization growth).
- Timing: deadline 14.06.2026.
Exit opportunities
- Strategic acquisition by major healthcare players or insurers (UHC, Cigna, Aetna) at 30–40x EBITDA — implied valuation of approximately $1.5–2B
- IPO positioning by 2029
- Consolidation of the digital metabolic health market
Potential multiple: ~6x under favorable market conditions.
Additional project information is available after registration in the app via the link or QR code.
Join the private Telegram chat to learn about other relevant investment opportunities: https://t.me/+qNeq1Ir3irZhMTBi
